At a glance
Effects
- Senescent-cell clearance: Selectively induces apoptosis in FOXO4-overexpressing senescent cells while leaving healthy proliferating cells unaffected in animal and in-vitro models [1][3].
- Physical fitness restoration (preclinical): In naturally aged and chemotherapy-stressed mice, treatment restored fur density, physical activity levels, and renal function within weeks [7][8].
- Vascular / endothelial rejuvenation (preclinical): Studies in aged mouse models show FOXO4-DRI alleviates endothelial cell senescence and improves vascular function [5].
- Testosterone support (preclinical): In aged mice, clearance of senescent Leydig cells improved the testicular microenvironment and alleviated age-related testosterone-secretion insufficiency [6].
- Reduction of pro-inflammatory SASP: Clearing senescent cells reduces their senescence-associated secretory phenotype (SASP) — the chronic inflammatory cytokine cloud that drives tissue ageing — in animal models [1][3].
Experimental senolytic peptide (D-retro-inverso)
Subcutaneous injection (oral/nasal/transdermal not viable — peptide degradation)
Not FDA-approved; research-use only; no completed human trials (as of June 2026)
Cellular uptake ~2–4 h; detectable 72+ h; D-amino acid structure confers protease resistance vs. L-peptides
Developed by de Keizer et al., Erasmus University Medical Center; first published in Cell, 2017
About FOXO4-DRI
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic 46-amino-acid senolytic peptide engineered to selectively eliminate senescent ("zombie") cells by triggering their programmed cell death [1]. It is a purely experimental, preclinical research compound — not approved for human use by any regulatory agency — that sits at the frontier of longevity and cellular-rejuvenation research [2].
How it works
Senescent cells overexpress the transcription factor FOXO4, which physically sequesters the tumour-suppressor protein p53 in the nucleus and blocks apoptosis, allowing dysfunctional "zombie" cells to accumulate [3]. FOXO4-DRI mimics the p53-binding domain of FOXO4 using D-amino acids in a reversed ("retro-inverso") sequence, making it highly resistant to enzymatic degradation [4]. Once inside a senescent cell, it competitively displaces endogenous FOXO4 from p53; freed p53 is then excluded from the nucleus, translocates to mitochondria, and activates the intrinsic apoptosis cascade (p53/BCL-2/Caspase-3 pathway) — killing the senescent cell while sparing healthy cells that do not rely on FOXO4–p53 binding for survival [5][6].
Risks & side effects
Most important: FOXO4-DRI has never been tested in a human clinical trial; all safety data comes from mouse studies and community self-reports, meaning human toxicity, optimal dosing, immunogenicity, and long-term oncogenic risk are completely unknown [2][9]. Because the peptide intervenes in the p53 tumour-suppressor pathway, researchers have explicitly flagged a theoretical risk that perturbing p53 dynamics in humans could carry oncogenic consequences [10].
Common
- Injection-site soreness lasting several days — the most frequently self-reported effect; site rotation is recommended [11]
- Flu-like symptoms within 24–48 hours of injection, interpreted as the immune response to dying senescent cells releasing their contents [11]
- Transient fatigue and energy fluctuations in the first few days of a cycle [11]
- Mild GI discomfort reported anecdotally [12]
Serious
- Completely unknown human safety profile — no clinical trial has been completed or registered as of June 2026 [9]
- Theoretical off-target apoptosis: although senescent cells are selectively targeted, heterogeneous populations may share FOXO4 features; unintended killing of healthy or quiescent cells cannot be ruled out [10]
- Theoretical oncogenic risk from modulating the p53 tumour-suppressor pathway in humans [10]
- Immune burden from simultaneous clearance of large numbers of senescent cells (senescent-cell lysis products entering circulation) [9]
- Potential disruption of wound healing and tissue repair — some senescent cells play beneficial transient roles in these processes [10]
Rare
- Immunogenicity to the D-retro-inverso peptide scaffold — biodistribution and immune reactions in humans have not been evaluated [10]
- Product-quality risk: synthesis of high-purity D-retro-inverso peptides is technically demanding; batch impurities in unregulated supply chains may cause unpredictable reactions [10]
- Theorised hormonal disruption if senolytic action inadvertently affects non-target endocrine cell populations [13]
Safety & harm reduction
- Pregnancy or breastfeeding — anti-senescence effects may interfere with hormonal signalling required for conception and fetal development [13]
- Anyone not enrolled in a formal clinical trial or physician-supervised research protocol — no human safety data exists [2][9]
- Immunosuppressed individuals without specialist supervision — unknown immune burden risk [4]
- Active cancer or personal/family history of p53-pathway tumours — theoretical oncogenic risk from p53 pathway modulation [10]
- Baseline and periodic inflammatory markers (CRP, IL-6) to gauge SASP burden before and after use [13]
- Full blood count to monitor for unexpected cell-death burden or haematological changes [13]
- Renal and hepatic function panels — clearance of senescent cells may transiently stress these organs [13]
- Hormonal panel (testosterone, LH, FSH) — preclinical data shows Leydig-cell effects [6]
- Other senolytics (e.g., dasatinib + quercetin, navitoclax, fisetin) — stacking is entirely speculative; combined senescent-cell kill may overwhelm immune clearance capacity [12]
- Chemotherapy or immunosuppressive agents — pharmacodynamic interactions unknown; p53-pathway overlap is a concern [10]
- Growth factors or anabolic peptides — no interaction data; theoretical competition for cellular survival pathways [13]
- Animal studies used 5 mg/kg intraperitoneal, 3×/week; community-reported human ranges are 1–8 mg per dose subcutaneously — mouse-to-human dose scaling is not validated and should not be applied directly [14][11]
- Cyclic administration (e.g., 5-days-on / rest) has been proposed to allow tissue recovery between treatment periods; continuous use may disrupt normal cellular turnover [8]
- Reconstitute lyophilised peptide in sterile or bacteriostatic water only; store at −20 °C; D-retro-inverso peptides are large (≈5.3 kDa) and require care during handling [14]
- Administer via subcutaneous injection using a 29–31 gauge insulin syringe; rotate sites (abdomen, upper thigh) to reduce localised soreness [11]
- Any use outside a formal clinical trial is entirely experimental and off-label — consult a licensed physician before any administration [2][9]
Dosage context
No validated human dose exists. The foundational 2017 mouse study used 5 mg/kg by intraperitoneal injection three times per week [14]. Community self-experimentation reports cluster around 1–8 mg per subcutaneous dose, but mouse-to-human scaling is not straightforward and carries unknown risk [11][14]. Human pharmacokinetics, maximum tolerated dose, and safe dosing intervals have not been established in any clinical trial [9]. These figures are reported for reference only and must not be interpreted as a recommendation.
Sources
- 1.Revolution Health — FOXO4-DRI Senolytic Peptide overview (Dec 2025)
- 2.Beverly Hills Rejuvenation Center — FOXO4-DRI regulatory & safety context
- 3.Nature Communications 2025 — Disordered p53 TAD is target of FOXO4-DRI
- 4.Communications Biology 2025 — FOXO4-DRI & keloid senescent fibroblast apoptosis
- 5.PMC / Frontiers in Bioengineering 2025 — FOXO4-DRI & endothelial senescence via p53
- 6.Aging-US 2020 — FOXO4-DRI alleviates testosterone insufficiency via senescent Leydig cells
- 7.PubMed / PMC — Senolytic FOXO4-DRI removes senescent chondrocytes in vitro (2021)
- 8.Fight Aging! — Ongoing FOXO4-DRI research commentary (Feb 2026)
- 9.PeptideDosing Protocols — FOXO4-DRI human trial & safety status (Jun 2026)
- 10.PeptideWiki — FOXO4-DRI dosage guide & community side-effect reports (Apr 2026)
- 11.WhatPeptide — FOX04-DRI benefits, research & safety guide
- 12.ThePeptideCatalog — FOXO4-DRI dosing & stacking context (2026)
- 13.BiohackNow — Biohack therapy checklist: FOXO4-DRI & peptide protocols
- 14.Pep-Pedia — FOXO4-DRI research, dosing & protocols (selectivity data)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.